Abstract
Late onset Alzheimer’s disease (LOAD) is a non-familial, progressive neurodegenerative disease and the most prominent form of dementia in the elderly. Accumulating evidence suggests that LOAD not only results from the combined effects of variation in a number of genes and environmental factors, but also from epigenetic abnormalities such as histone modifications or DNA methylation. In comparison to monogenic diseases, LOAD exhibits numerous anomalies that suggest an epigenetic component in disease etiology. Evidence against a monogenic course and for an epigenetic component include: 1) the dominance of sporadic cases over familial ones and the low estimated concordance rates for monozygotic twins; 2) gender specific susceptibility and course of disease; 3) parent–of–origin effects, and late age of onset; 4) brain chromatin abnormalities, non–Mendelian inheritance patterns, and atypical levels of folate and homocysteine; and 5) monoallelic expression patterns of susceptibility genes [1]. The epigenome is particularly susceptible to deregulation during early embryonic and neonatal periods and thus disturbances during these periods can have latent lasting effects. The Latent Early-life Associated Regulation (LEARn) model attempts to explain these consequences from a brain specific point of view. In the present review we present the evidence that support the role of epigenetics in the development of AD and explore the potential pathways and mechanisms that may be involved.
Keywords: Alzheimer’s disease, cognitive function, amyloid hypothesis, APP, LOAD.
Current Alzheimer Research
Title:Do Epigenetic Pathways Initiate Late Onset Alzheimer Disease (LOAD): Towards a New Paradigm
Volume: 9 Issue: 5
Author(s): Syed Waseem Bihaqi, Axel Schumacher, Bryan Maloney, Debomoy K. Lahiri and Nasser H. Zawia
Affiliation:
Keywords: Alzheimer’s disease, cognitive function, amyloid hypothesis, APP, LOAD.
Abstract: Late onset Alzheimer’s disease (LOAD) is a non-familial, progressive neurodegenerative disease and the most prominent form of dementia in the elderly. Accumulating evidence suggests that LOAD not only results from the combined effects of variation in a number of genes and environmental factors, but also from epigenetic abnormalities such as histone modifications or DNA methylation. In comparison to monogenic diseases, LOAD exhibits numerous anomalies that suggest an epigenetic component in disease etiology. Evidence against a monogenic course and for an epigenetic component include: 1) the dominance of sporadic cases over familial ones and the low estimated concordance rates for monozygotic twins; 2) gender specific susceptibility and course of disease; 3) parent–of–origin effects, and late age of onset; 4) brain chromatin abnormalities, non–Mendelian inheritance patterns, and atypical levels of folate and homocysteine; and 5) monoallelic expression patterns of susceptibility genes [1]. The epigenome is particularly susceptible to deregulation during early embryonic and neonatal periods and thus disturbances during these periods can have latent lasting effects. The Latent Early-life Associated Regulation (LEARn) model attempts to explain these consequences from a brain specific point of view. In the present review we present the evidence that support the role of epigenetics in the development of AD and explore the potential pathways and mechanisms that may be involved.
Export Options
About this article
Cite this article as:
Waseem Bihaqi Syed, Schumacher Axel, Maloney Bryan, K. Lahiri Debomoy and H. Zawia Nasser, Do Epigenetic Pathways Initiate Late Onset Alzheimer Disease (LOAD): Towards a New Paradigm, Current Alzheimer Research 2012; 9 (5) . https://dx.doi.org/10.2174/156720512800617982
DOI https://dx.doi.org/10.2174/156720512800617982 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Herbal Medicines for Diabetes Management and its Secondary Complications
Current Diabetes Reviews Adipokines, Metabolism and the Immune Response in the Regulation of Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Polypharmacy in Cardiovascular Medicine: Problems and Promises!
Cardiovascular & Hematological Agents in Medicinal Chemistry Non Enzymatic Glycated Proteins in the Blood and Cardiovascular Disease
Current Pharmaceutical Design Evidence on the Protective Role of High-Density Lipoprotein (HDL) in HIV-Infected Individuals
Current Vascular Pharmacology Recent Advances in Treatment Approaches to Gaucher Disease
Current Pharmaceutical Biotechnology Repetitive Transient Phosphodiesterase-3 Inhibition Eliminates Non-ischemic Cardiac Remodeling and Failure
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Regulatory Mechanisms of Cardiac Development and Repair
Cardiovascular & Hematological Disorders-Drug Targets Systemic Fungal Infections Caused by Candida Species: Epidemiology, Infection Process and Virulence Attributes
Current Drug Targets Relationship Between Proinsulin Level and Cardiovascular Risk Factors Clustering: An Epidemiological Study
Vascular Disease Prevention (Discontinued) Regulation of Angiotensin II Receptor Expression
Current Pharmaceutical Design Development of Arene Ruthenium Antitumor Complexes
Mini-Reviews in Medicinal Chemistry Anti-inflammatory Glycosylated Flavonoids as Therapeutic Agents for Treatment of Diabetes-Impaired Wounds
Current Topics in Medicinal Chemistry Advanced Glycation End Products and Insulin Resistance
Current Pharmaceutical Design The MAPK / JNK Signalling Pathway Offers Potential Therapeutic Targets for the Prevention of Acquired Deafness
Current Drug Targets - CNS & Neurological Disorders Development and Validation of a RP-HPLC Method for Simvastatin Capsules
Current Pharmaceutical Analysis The Critical Roles of HSC70 in Physiological and Pathological Processes
Current Pharmaceutical Design Metabolism of HDL and its Regulation
Current Medicinal Chemistry Antisense Oligonucleotides for the Treatment of Dyslipidemia
Current Pharmaceutical Design Adverse Drug Reactions in a Pulmonary Teaching Hospital: Incidence, Pattern, Seriousness, and Preventability
Current Drug Safety